Companies

BEAM · Biotech

Beam Therapeutics Inc.

SEC company filings

Research coverage

Classification review pending

Price Chart
Available
Reported Cash
Available
Pipeline
Available
Catalysts
Scanned — no results

Reported cash

USD 213,267,000

Sep 30, 2026

SEC filing

Cash and cash equivalents · Restricted cash and marketable securities excluded

Cash verified Nov 16, 2026

Price chart

What changed?

No verified development in tracked sources.

Upcoming catalysts

No upcoming event verified in tracked sources.

Drug pipeline

5 programs · 5 verified studies

BEAM-101

Phase

Phase1 / Phase2

Study status

Active not recruiting
View details

Beam Therapeutics Inc.

IndicationSickle Cell Disease

Estimated study completion2028-02

BEAM-103

Phase

Phase1

Study status

Recruiting
View details

Beam Therapeutics Inc.

IndicationHealthy Subjects; Healthy Participant Study

Estimated study completion2026-05-29

BEAM-201

Phase

Phase1 / Phase2

Study status

Active not recruiting
View details

Beam Therapeutics Inc.

IndicationLymphoblastic Lymphoma; T-Cell Lymphoblastic Leukemia/Lymphoma; Lymphoblastic Leukemia

Estimated study completion2026-12

BEAM-301: Single dose of BEAM-301 administered by IV

Phase

Phase1 / Phase2

Study status

Recruiting
View details

Beam Therapeutics Inc.

IndicationGlycogen Storage Disease Type Ia

Estimated study completion2027-12-30

BEAM-302

Phase

Phase1 / Phase2

Study status

Recruiting
View details

Beam Therapeutics Inc.

IndicationAlpha 1-Antitrypsin Deficiency

Estimated study completion2030-05

2 unverified sponsor matches remain unlinked.

Verified timeline

0 records

No verified developments in tracked sources.